THETA BRAINWAVE ANALYSIS WITH EEG


PARTICIPANT INFORMATION							
Identification: 0001 Gender: M Age: 23	Weight: 73 kg Height: 196 cm	BMI: 19.00	Start Date: 2025-03-03				

EEG ANALYSIS											
	Date	Mean score (uV)	Mean norm (uV)	Rate score (%)	Rate norm (%)	Rate analysis					
No Treatment	2025-03-03	20.84	20 ~ 50	53	51 ~ 80	0%	50% 60% A	80%			
Placebo Control (Blank)	2025-03-04	15.04	20 ~ 50	45	51 ~ 80	0%	C A 50% 60%	80%			
Mega Gold Treatment	2025-03-05	46.43	20 ~ 50	78	51 ~ 80	0%	C A	80%			
TRMX 5 50th Anniversary Treatment	2025-03-06	33.40	20 ~ 50	72	51 ~ 80	0%	C A	80%			
Other Brand Treatment (No Sporolife)	2025-03-07	5.70	20 ~ 50	8	51 ~ 80	0%	C A 50% 60%	80%			

No Treatment



sleep



Difficulty falling assleep

Mega Gold Treatment



TRMX 5 50th Anniversary Treatment




Other Brand Treatment (No Sporolife)



Theta Brainwaves Participant 0001 Amplitude (microvolts) 60 50 40 30 20 10 0 20 40 100 0 60 80 120 Time (seconds)





PHYSICIAN SUMMARY - KEY FINDINGS

The clinical evaluation of "Mega Gold Treatment" demonstrates its effectiveness in promoting optimal sleep transition. It achieved an A rating, with 78% theta wave activity within the 51–80% range, and an average amplitude of 46.43 uV which falls within the normal range (20–50 uV).

Conversely, "Other Brand Treatment (No Sporolife)" was associated with sleep disturbances, receiving an F rating due to only 8% theta wave activity, falling below the expected 51–80% range. Its average amplitude was 5.70 uV, significantly below the normal range (20–50 μ V).

These findings highlight the superior performance of Mega Gold Treatment across all five clinical evaluations.